Search

Home > New FDA Approvals > 058 - FDA adds study data to schizophrenia drug paliperidone labeling; Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA); various FDA press releases from Jan 4th, 2018.


	Podcast:		New FDA Approvals
	Episode:		058 - FDA adds study data to schizophrenia drug paliperidone labeling; Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA); various FDA press releases from Jan 4th, 2018.
	Category:		Science & Medicine
	Duration:		00:09:29
	Publish Date:		2018-01-05 07:00:00
	Description:		January 5, 2018 0:42 - FDA Adds Study Data to Schizophrenia Drug Labeling http://www.janssen.com/landmark-schizophrenia-data-bring-hope-breaking-cycle-hospitalization-and-incarceration-receive-fda https://www.medscape.com/viewarticle/890882 3:36 - Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) https://www.novartis.com/news/media-releases/novartis-drug-promactar-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa 5:38 - Various FDA news releases from Jan 4 2018. January 04, 2018 - Statement by FDA Commissioner Scott Gottlieb, M.D., update on recovery efforts in Puerto Rico, and continued efforts to mitigate IV saline and amino acid drug shortages January 04, 2018 - Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA Food Safety Modernization Act enforcement discretion guidance January 04, 2018 - FDA warns American CryoStem Corporation of significant deviations related to its unapproved stem cell product, Atcell Check out the podcast's website at newfdaapprovals.com Nascent Medical info@nascentmc.com 6 Week Course "Everything you need to know to start your freelance medical writing business" starts January 15th, 2018 - info here: 6weekcourse.com
	Total Play:		0